Germany’s CureVac jab shows only 48% effectiveness against Covid-19 in final stage of trial, driving stock plunge
CureVac announced the second- and third-phase trial results for its CVnCoV vaccine on Wednesday, in its final analysis for a 40,000-subject study that drew participants from 10 countries across Europe and Latin America.
“In the unprecedented context of…
